- Home
- RVMDW vs OCEAW Comparison
RVMDW vs OCEAW Comparison
Compare RVMDW & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVMDW
- OCEAW
- Stock Information
- Founded
- RVMDW 2014
- OCEAW N/A
- Country
- RVMDW United States
- OCEAW United States
- Employees
- RVMDW 534
- OCEAW 7
- Industry
- RVMDW
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- RVMDW
- OCEAW Health Care
- Exchange
- RVMDW Nasdaq
- OCEAW Nasdaq
- Market Cap
- RVMDW N/A
- OCEAW N/A
- IPO Year
- RVMDW N/A
- OCEAW 2021
- Fundamental
- Price
- RVMDW $0.10
- OCEAW $0.03
- Analyst Decision
- RVMDW
- OCEAW
- Analyst Count
- RVMDW 0
- OCEAW 0
- Target Price
- RVMDW N/A
- OCEAW N/A
- AVG Volume (30 Days)
- RVMDW 15.6K
- OCEAW N/A
- Earning Date
- RVMDW 02-26-2025
- OCEAW N/A
- Dividend Yield
- RVMDW N/A
- OCEAW N/A
- EPS Growth
- RVMDW N/A
- OCEAW N/A
- EPS
- RVMDW N/A
- OCEAW N/A
- Revenue
- RVMDW $742,000.00
- OCEAW N/A
- Revenue This Year
- RVMDW N/A
- OCEAW N/A
- Revenue Next Year
- RVMDW N/A
- OCEAW N/A
- P/E Ratio
- RVMDW N/A
- OCEAW N/A
- Revenue Growth
- RVMDW N/A
- OCEAW N/A
- 52 Week Low
- RVMDW $0.10
- OCEAW N/A
- 52 Week High
- RVMDW $0.12
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- RVMDW N/A
- OCEAW N/A
- Support Level
- RVMDW N/A
- OCEAW N/A
- Resistance Level
- RVMDW N/A
- OCEAW N/A
- Average True Range (ATR)
- RVMDW 0.00
- OCEAW 0.00
- MACD
- RVMDW 0.00
- OCEAW 0.00
- Stochastic Oscillator
- RVMDW 0.00
- OCEAW 0.00
About RVMDW Revolution Medicines Inc. Warrant
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.